Tranilast suppresses the disease development of the adjuvant- and streptococcal cell wall-induced arthritis in rats

Journal of Pharmacological Sciences

Volumn 105, Issue 1, 2007, Pages 48-56

  Nagate, Toshiaki ^a,b   Tamura, Toru ^b   Sato, Fumiyasu ^b   Kuroda, Junji ^b   Nakayama, Jun ^a   Shibata, Nobuo ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Adjuvant induced arthritis; Methotrexate; Rheumatoid arthritis; Streptococcal cell wall induced arthritis; Tranilast

Indexed keywords

ADJUVANT; METHOTREXATE; TRANILAST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL CELL WALL; CONTROLLED STUDY; FIBROSIS; FOOT EDEMA; HISTOPATHOLOGY; NONHUMAN; PAW EDEMA; RAT; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SENSITIZATION; STREPTOCOCCUS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34648824447     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0070534     Document Type: Article

References (30)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85:307-310.
2. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am. 1993;19:123-151.
3. Schopf LR, Anderson K, Jaffee BD. Rat models of arthritis: Similarities, differences, advantages, and disadvantages in the identification of novel therapeutics. In: Stevenson CS, Marshall LA, Morgan DW, editors. In vivo models of inflammation. 2nd ed. Berlin: Birkhauser Verlag; 2006. p. 1-34.
4. Kannan K, Ortmann RA, Kimpel D. Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology. 2005;12:167-181.
5. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, et al. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum. 2000;43:175-183.
6. Noguchi M, Kimoto A, Kobayashi S, Yoshino T, Miyata K, Sasamata M. Effect of celecoxib, a cyclooxygenase-2 inhibitor, on the pathophysiology of adjuvant arthritis in rat. Eur J Pharmacol. 2005;513:229-235.
7. Follettie MT, Pinard M, Keith JC Jr, Wang L, Chelsky D, Hayward C, et al. Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-beta selective agonist ERB-041. Endocrinology. 2006;147:714-723.
8. Ridge SC, Rath N, Galivan J, Zabriske J, Oronsky AL, Kerwar SS. Studies on the effect of D-penicillamine, gold thioglucose and methotrexate on streptococcal cell wall arthritis. J Rheumatol. 1986;13:895-898.
9. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol. 2003;30:2193-2200.
10. Pfab T, Hocher B. Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug. J Hypertens. 2004;22:883-886.
11. Suzawa H, Kikuchi S, Ichikawa K, Koda A. Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn J Pharmacol. 1992;60:85-90.
12. Shimizu T, Kanai K, Kyo Y, Asano K, Hisamitsu T, Suzaki H. Effect of tranilast on matrix metalloproteinase production from neutrophils in-vitro. J Pharm Pharmacol. 2006 Jan;58:91-99.
13. Kagitani S, Ueno H, Hirade S, Takahashi T, Takata M, Inoue H. Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/ salt hypertensive rats. J Hypertens. 2004;22:1007-1015.
14. Platten M, Ho PP, Youssef S, Fontoura P, Garren H, Hur EM, et al. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. 2005;310:850-855.
15. Yeom MJ, Lee HC, Kim GH, Lee HJ, Shim I, Oh SK, et al. Antiarthritic effects of Ephedra sinica STAPF herb-acupuncture: inhibition of lipopolysaccharide-induced inflammation and adjuvant-induced polyarthritis. J Pharmacol Sci. 2006;100:41-50.
16. Langdon C, Kerr C, Hassen M, Hara T, Arsenault AL, Richards CD. Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol. 2000;157:1187-1196.
17. Gong JH, Ratkay LG, Waterfield JD, Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med. 1997;186:131-137.
18. Isaji M, Miyata H, Ajisawa Y, Takehana Y, Yoshimura N. Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo. Br J Pharmacol. 1997;122:1061-1066.
19. Bodolay E, Koch AE, Kim J, Szegedi G, Szekanecz Z. Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med. 2002;6:357-376.
20. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798-1801.
21. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest. 1999;103:47-54.
22. DeJoy SQ, Ferguson KM, Theresa MS, Zabriskie JB, Oronsky AL, Kerwar SS. Streptococcal cell wall arthritis, Passive transfer of disease with a T cell line and crossreactivity of streptococcal cell wall antigens with Mycobacterium tuberculosis. J Exp Med. 1989;170:369-382.
23. Allen JB, Malone DG, Whal SM, Calandra GB, Wilder RL. Role of the thymus in streptococcal cell wall-induced arthritis and hepatic granuloma formulation. J Clin Invest. 1985;76:1042-1056.
24. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002;46:328-346.
25. Cutolo M, Sulli A, Pizzorni C, Seriolo B. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis. 2001;60:729-735.
26. Ukai K, Masuda S, Shinoki J, Sakakura Y. Clinical and pathophysiological evaluation of tranilast in patients with pollinosis: the effects of pre-seasonal treatment. Auris Nasus Larynx. 1993;20:275-284.
27. Goto S, Takakura K, Hirose M, Kimura T, Takebayashi K, Akiyama M, et al. Preventive effect of tranilast on keloid and hypertrophic scar formation after gynecological surgery, Multicenter study. Adv Obstet Gynecol. 2001;53:197-202.
28. Bendele A. Animal models of rheumatoid arthritis. J Musculoskelet Neuronal Interact. 2001;1:377-385.
29. Mori H, Tanaka H, Kawada K, Nagai H, Koda A. Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis. Jpn J Pharmacol. 1995;67:279-289.
30. Mori H, Kawada K, Zhang P, Uesugi Y, Sakamoto O, Koda A. Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis. Int Arch Allergy Appl Immunol. 1991;95:195-201.